Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

Forge Resources Intercepts 105 G/T Au in the Payoff Zone at Alotta Project, Yukon (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Price History | Ratios | Ownership | Insiders

Bullboard - Stock Discussion Forum Eli Lilly and Co LLY

Healthcare Biotechnology

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE... see more

Add To Watchlist

Bullboard (NYSE:LLY)

View:

Post by EvansWilsonon Aug 21, 2025 3:00am

Don’t Miss the Next Eli Lilly Payout Date

For investors tracking Eli lilly dividend date, the next key date to note is August15,2025—that’s the exdividend and record date for the upcoming quarterly payout of $1.50 per share, scheduled to be ...more

40

(111)
•••

Post by jboom70on Feb 21, 2025 9:43pm

LLY

Is setting up to run again.

51

Forge Resources Intercepts 105 G/T Au in the Payoff Zone at Alotta Project, Yukon

posted Nov 17, 2025 9:00am by Forge Resources Corp.

Forge Resources announces the first gold assay results from the Phase 2 diamond drill program at Alotta, intercepting 105 g/t Au over a core length of 1.25 m. Majority of assays results are still pending ...read more

Post by PressReleaseon Oct 02, 2024 7:30am

New Press Release - Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials

Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more...read article.

Post by PressReleaseon Sep 25, 2024 6:45am

New Press Release - New data show Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year...read article.

Post by PressReleaseon Sep 24, 2024 6:00am

New Press Release - Lilly's Kisunla(TM) (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease

Japan is the second major market where Kisunla has received approvalKisunla was first approved in the United States in July 2024INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks...read article.

Post by PressReleaseon Sep 13, 2024 4:08pm

New Press Release - FDA Approves Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicalsPatients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeksEBGLYSS delivers long...read article.

Post by PressReleaseon Sep 12, 2024 5:30am

New Press Release - Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facilityNew investment will enhance global medicine production, benefiting millions of patients worldwideINDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced...read article.

Post by PressReleaseon Sep 10, 2024 11:57am

New Press Release - With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes

Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial...read article.

Post by PressReleaseon Sep 10, 2024 11:19am

New Press Release - Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD...read article.

Post by PressReleaseon Sep 09, 2024 6:45am

New Press Release - Lilly appoints Lucas Montarce as executive vice president and chief financial officer

INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately.Since joining Lilly in 2001...read article.

Post by PressReleaseon Sep 05, 2024 6:45am

New Press Release - In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin

In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first timeIn a second phase 3 study, QWINT-3, efsitora also delivered non-inferior A1C reduction compared to daily...read article.

Post by PressReleaseon Sep 04, 2024 6:00am

New Press Release - Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in AfricaINDIANAPOLIS and CAIRO, Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and...read article.

Post by PressReleaseon Aug 27, 2024 6:45am

New Press Release - Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity

Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesityINDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5...read article.

Post by PressReleaseon Aug 22, 2024 10:01am

New Press Release - Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference

INDIANAPOLIS, Aug. 22, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 5, 2024. Jacob Van Naarden, executive vice president and president, Lilly Oncology, will participate in a fireside chat at 7:45 a.m...read article.

Post by PressReleaseon Aug 20, 2024 6:45am

New Press Release - Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight

176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date Tirzepatide resulted in sustained weight loss through the treatment period, averaging a 22.9% decrease in body weight with the 15 mg dose at end of treatmentResults are consistent...read article.

Market Update

{{currentVideo.title}} {{currentVideo.relativeTime}}

A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}

{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}

{{currentVideo.headline}}

{{currentVideo.link1Text}}

{{currentVideo.link2Text}}

< Previous

{{moreVideoText}}

Next >

Featured News Links

Silver North Intersects 13.15 m Averaging 818 g/t Silver and 1.39 g/t Gold at the Haldane Property